291 related articles for article (PubMed ID: 25435423)
1. ErbB2 signaling activates the Hedgehog pathway via PI3K-Akt in human esophageal adenocarcinoma: identification of novel targets for concerted therapy concepts.
Kebenko M; Drenckhan A; Gros SJ; Jücker M; Grabinski N; Ewald F; Grottke A; Schultze A; Izbicki JR; Bokemeyer C; Wellbrock J; Fiedler W
Cell Signal; 2015 Feb; 27(2):373-81. PubMed ID: 25435423
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of sonic hedgehog and PI3K/Akt/mTOR pathways cooperate in suppressing survival, self-renewal and tumorigenic potential of glioblastoma-initiating cells.
Nanta R; Shrivastava A; Sharma J; Shankar S; Srivastava RK
Mol Cell Biochem; 2019 Apr; 454(1-2):11-23. PubMed ID: 30251117
[TBL] [Abstract][Full Text] [Related]
3. Identification of a novel synthetic lethality of combined inhibition of hedgehog and PI3K signaling in rhabdomyosarcoma.
Graab U; Hahn H; Fulda S
Oncotarget; 2015 Apr; 6(11):8722-35. PubMed ID: 25749378
[TBL] [Abstract][Full Text] [Related]
4. Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition.
Ebbing EA; Steins A; Fessler E; Stathi P; Lesterhuis WJ; Krishnadath KK; Vermeulen L; Medema JP; Bijlsma MF; van Laarhoven HWM
Gastroenterology; 2017 Jul; 153(1):63-76.e14. PubMed ID: 28286209
[TBL] [Abstract][Full Text] [Related]
5. Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2-positive gastric cancer.
Zhu Y; Tian T; Zou J; Wang Q; Li Z; Li Y; Liu X; Dong B; Li N; Gao J; Shen L
BMC Cancer; 2015 Nov; 15():894. PubMed ID: 26560145
[TBL] [Abstract][Full Text] [Related]
6. Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models.
Schrauwen S; Depreeuw J; Coenegrachts L; Hermans E; Lambrechts D; Amant F
Gynecol Oncol; 2015 Jul; 138(1):165-73. PubMed ID: 25933683
[TBL] [Abstract][Full Text] [Related]
7. PI3K/AKT/mTOR and sonic hedgehog pathways cooperate together to inhibit human pancreatic cancer stem cell characteristics and tumor growth.
Sharma N; Nanta R; Sharma J; Gunewardena S; Singh KP; Shankar S; Srivastava RK
Oncotarget; 2015 Oct; 6(31):32039-60. PubMed ID: 26451606
[TBL] [Abstract][Full Text] [Related]
8. Targeting hedgehog signaling pathway in pediatric tumors: in vitro evaluation of SMO and GLI inhibitors.
Arnhold V; Boos J; Lanvers-Kaminsky C
Cancer Chemother Pharmacol; 2016 Mar; 77(3):495-505. PubMed ID: 26781311
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo inhibition of breast cancer cell growth by targeting the Hedgehog/GLI pathway with SMO (GDC-0449) or GLI (GANT-61) inhibitors.
Benvenuto M; Masuelli L; De Smaele E; Fantini M; Mattera R; Cucchi D; Bonanno E; Di Stefano E; Frajese GV; Orlandi A; Screpanti I; Gulino A; Modesti A; Bei R
Oncotarget; 2016 Feb; 7(8):9250-70. PubMed ID: 26843616
[TBL] [Abstract][Full Text] [Related]
10. DYRK1B blocks canonical and promotes non-canonical Hedgehog signaling through activation of the mTOR/AKT pathway.
Singh R; Dhanyamraju PK; Lauth M
Oncotarget; 2017 Jan; 8(1):833-845. PubMed ID: 27903983
[TBL] [Abstract][Full Text] [Related]
11. Chemical probing of HER2-amplified cancer cells identifies TORC2 as a particularly effective secondary target for combination with lapatinib.
Amin DN; Ruiz-Saenz A; Gulizia N; Moasser MM
Oncotarget; 2015 Dec; 6(38):41123-33. PubMed ID: 26516700
[TBL] [Abstract][Full Text] [Related]
12. Biomarker-guided sequential targeted therapies to overcome therapy resistance in rapidly evolving highly aggressive mammary tumors.
Sahin O; Wang Q; Brady SW; Ellis K; Wang H; Chang CC; Zhang Q; Priya P; Zhu R; Wong ST; Landis MD; Muller WJ; Esteva FJ; Chang J; Yu D
Cell Res; 2014 May; 24(5):542-59. PubMed ID: 24675532
[TBL] [Abstract][Full Text] [Related]
13. GLI1 promotes cancer stemness through intracellular signaling pathway PI3K/Akt/NFκB in colorectal adenocarcinoma.
Yang Z; Zhang C; Qi W; Cui Y; Xuan Y
Exp Cell Res; 2018 Dec; 373(1-2):145-154. PubMed ID: 30321514
[TBL] [Abstract][Full Text] [Related]
14. A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib.
Elster N; Cremona M; Morgan C; Toomey S; Carr A; O'Grady A; Hennessy BT; Eustace AJ
Breast Cancer Res Treat; 2015 Jan; 149(2):373-83. PubMed ID: 25528022
[TBL] [Abstract][Full Text] [Related]
15. Non-canonical GLI1/2 activation by PI3K/AKT signaling in renal cell carcinoma: A novel potential therapeutic target.
Zhou J; Zhu G; Huang J; Li L; Du Y; Gao Y; Wu D; Wang X; Hsieh JT; He D; Wu K
Cancer Lett; 2016 Jan; 370(2):313-23. PubMed ID: 26577809
[TBL] [Abstract][Full Text] [Related]
16. GLI inhibitor GANT-61 diminishes embryonal and alveolar rhabdomyosarcoma growth by inhibiting Shh/AKT-mTOR axis.
Srivastava RK; Kaylani SZ; Edrees N; Li C; Talwelkar SS; Xu J; Palle K; Pressey JG; Athar M
Oncotarget; 2014 Dec; 5(23):12151-65. PubMed ID: 25432075
[TBL] [Abstract][Full Text] [Related]
17. Efficient elimination of pancreatic cancer stem cells by hedgehog/GLI inhibitor GANT61 in combination with mTOR inhibition.
Miyazaki Y; Matsubara S; Ding Q; Tsukasa K; Yoshimitsu M; Kosai K; Takao S
Mol Cancer; 2016 Jun; 15(1):49. PubMed ID: 27349387
[TBL] [Abstract][Full Text] [Related]
18. Expression of Hedgehog Pathway Mediator GLI Represents a Negative Prognostic Marker in Human Acute Myeloid Leukemia and Its Inhibition Exerts Antileukemic Effects.
Wellbrock J; Latuske E; Köhler J; Wagner K; Stamm H; Vettorazzi E; Vohwinkel G; Klokow M; Uibeleisen R; Ehm P; Riecken K; Loges S; Thol F; Schubert C; Amling M; Jücker M; Bokemeyer C; Heuser M; Krauter J; Fiedler W
Clin Cancer Res; 2015 May; 21(10):2388-98. PubMed ID: 25745035
[TBL] [Abstract][Full Text] [Related]
19. Smoothened-independent activation of hedgehog signaling by rearranged during transfection promotes neuroblastoma cell proliferation and tumor growth.
Ruan H; Luo H; Wang J; Ji X; Zhang Z; Wu J; Zhang X; Wu X
Biochim Biophys Acta; 2016 Sep; 1860(9):1961-72. PubMed ID: 27316313
[TBL] [Abstract][Full Text] [Related]
20. The angiotensin II type 1 receptor antagonist telmisartan inhibits cell proliferation and tumor growth of esophageal adenocarcinoma via the AMPKα/mTOR pathway in vitro and in vivo.
Fujihara S; Morishita A; Ogawa K; Tadokoro T; Chiyo T; Kato K; Kobara H; Mori H; Iwama H; Masaki T
Oncotarget; 2017 Jan; 8(5):8536-8549. PubMed ID: 28052030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]